TABLE 4.
Treatments and outcomes of recovery and death patients with severe or critical COVID-19.
| Characteristics | Total (n = 74) | Recovery (n = 60) | Death (n = 14) | P Value |
|---|---|---|---|---|
| Medical treatment | ||||
| Antiviral therapy | 74 (100%) | 60 (100%) | 14 (100%) | 1.000 |
| Lopinavir and Ritonavir | 68 (91.9%) | 57 (95.0%) | 11 (78.6%) | 0.043 |
| Ganciclovir | 4 (5.4%) | 2 (3.3%) | 2 (14.3%) | 0.103 |
| Arbidol | 2 (2.7%) | 1 (1.7%) | 1 (7.1%) | 0.255 |
| Antiviral drug atomization therapy | 68 (91.9%) | 56 (93.3%) | 12 (85.7%) | 0.347 |
| Antibiotic therapy | 68 (91.9%) | 54 (90.0%) | 14 (100%) | 0.271 |
| Corticosteroids therapy | 70 (94.6%) | 58 (96.7%) | 12 (85.7%) | 0.103 |
| Total duration of corticosteroids, days | 11 (8-15) | 11 (8-15) | 10 (5-15) | 0.369 |
| Intravenous immunoglobulin therapy | 41 (55.4%) | 31 (51.7%) | 10 (71.4%) | 0.180 |
| Oxygen inhalation | ||||
| High flow nasal catheter | 67 (90.5%) | 58 (96.7%) | 9 (64.3%) | <0.001 |
| Noninvasive mechanical ventilation | 14 (18.9%) | 5 (8.3%) | 9 (64.3%) | <0.001 |
| Invasive mechanical ventilation | 6 (8.1%) | 0 (0.0%) | 6 (42.9%) | <0.001 |
| Extracorporeal membrane oxygenation | 2 (2.7%) | 0 (0.0%) | 2 (14.3%) | 0.020 |
| Outcomes | ||||
| Hospital stay, days | 15 (11-22) | 16 (12-22) | 13 (10-23) | 0.267 |
| Severe cases | 48 (64.9%) | 47 (78.3%) | 1 (7.1%) | <0.001 |
| Critical cases | 26 (35.1%) | 13 (21.7%) | 13 (92.9%) | <0.001 |
Data are reported as n (%) or median (IQR). The P value represents the difference between COVID-19 recovery and death patients. P value <0.05 was considered significant different (Bold font).